Artesunate Injection is prescribed for the initial treatment of severe malaria in adults as well as pediatric patients.
In order to treat severe malaria, artesunate 60 mg should always be followed by a complete treatment course of an oral antimalarial regimen.
Dosage: The recommended artesunate dosage is 2.4 mg/kg, should be administered intravenously at 0 hours, 12 hours, and 24 hours, and thereafter, administered once in a day until the patient is able to tolerate oral antimalarial therapy. Administered constituted injections intravenously as a slow bolus over 1-2 minutes. Do not administer inj falcigo 60 mg via continuous intravenous infusion.
The most commonly observed artesunate side effects may include:
- Slow heartbeat
- Allergic reaction
- Low white blood cell levels
- Acute renal failure requiring dialysis
If you experience any of the adverse events listed above, report your healthcare provider right away.
Warnings and Precautions:
- The falcigo 120 mg injection does not treat the hypnozoite liver stage forms of Plasmodium and can not prevent relapses of malaria.
- Patients should be monitored for 4 weeks following treatment for the evidence of hemolytic anemia.
- In pregnancy, delaying treatment of severe malaria may be responsible for serious morbidity and mortality to the mother as well as fetus.
- The artesunate uses should be avoided in patients with known previous hypersensitivity reactions to this drug, dihydroartemisinin or any other components of the formulation.
- Care must be imposed in patients with the hepatic impairment because of the potential effects of hepatotoxic.